Effectiveness of Cilostazol on cerebral vasospasm after subarachnoid hemorrhage

Effectiveness of Cilostazol on cerebral vasospasm after subarachnoid hemorrhage - Effect of Cilostazol on vasospasm after subarachnoid hemorrhage

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004347

Enrollment

100

Registered

2010-10-07

Start date

2009-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

subarachnoid hemorrhage

Interventions

administration of cilostazol Administration of non-cilostazol (ordinary treatment)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients treated by clipping or coiling within 72 hours after SAH. 2. Patients classified as Hunt and kosnik grade 1 to 4. 3. Patients amenable to start cilostazol within 96 hours after SAH and within 48 hours after clipping or coiling.

Exclusion criteria

Exclusion criteria: 1. Patients with congestive heart failure, cilostazol hypersensitivity, pregnancy. 2. Patients with Hemophilia, gastrointestinal bleeding, history of intracerebral hemorrhage. 3. Patients with malignant tumor, liver failure, and renal failure. 4. patients judged improper candidate by doctor.

Design outcomes

Primary

Measure	Time frame
Frequency of delayed ischemic neurological deficits	—

Secondary

Measure	Time frame
1.Angiographical vasospasm on digital subtraction angiography or computed tomographic angiography 2.infarction caused by vasospasm 3.outcome (modified rankin scale) 4.length of hospitalization	—

Countries

Japan

Contacts

Public ContactKazuya Kanemaru

University of Yamanashi, Faculty of Medicine Neurosurgery

kanemaru@yamanashi.ac.jp055-273-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026